Views of policymakers, healthcare workers and NGOs on HIV pre-exposure prophylaxis (PrEP): A multinational qualitative study

BMJ Open

Volumn 2, Issue 4, 2012, Pages

  Wheelock, Ana ^a   Eisingerich, Andreas B ^b   Gomez, Gabriela B ^c   Gray, Emily ^d   Dybul, Mark R ^e,f   Piot, Peter ^g  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^d Ipsos   (United States)

^e GEORGETOWN UNIVERSITY LAW CENTER   (United States)

^f George W Bush Institute   (United States)

^g LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AWARENESS; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MALE HOMOSEXUAL; NON PROFIT ORGANIZATION; QUALITATIVE RESEARCH;

EID: 84864153836     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-001234     Document Type: Article

References (28)

1. UNAIDS, WHO, UNICEF. GLOBAL HIV/AIDS RESPONSE-Epidemic Update and Health Sector Progress Towards Universal Access. Geneva, Switzerland: UNAIDS, WHO, UNICEF, 2011.
2. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al; CAPRISA 004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329:1168-74.
3. Grant RM, Lama JR, Anderson PL, et al; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-99.
4. Cohen MS, Chen YQ, McCauley M, et al HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493-505.
5. Thigpen M, Kebaabetswe P, Smith D, et al. Daily Oral Antiretroviral Use for the Prevention of HIV Infection in Heterosexually Active Young Adults in Botswana: Results From the TDF2 Study. 6th IAS Conference. Rome, Italy. WELBC01 oral abstract. http://pag.ias2011. org/abstracts.aspx?aid=4631 (accessed 8 Dec 2011).
6. Baeton J, Celum C. Antiretroviral Pre-exposure Prophylaxis for HIV-1 Prevention Among Heterosexual African Men and Women: The Partners PrEP Study. 6th IAS Conference. Rome, Italy. Abstract MOAX0106. http://pag.ias2011.org/ flash.aspx?pid=886 (accessed 8 Dec 2011).
7. Van Damme L, Corneli A, Ahmed K, et al. The FEM-PrEP trial of emtricitabine/tenofovir disoproxil fumarate (Truvada) among African women. 19th Conference on Retroviruses and Opportunistic Infections; 5-8 March 2012, Seattle. Abstract 32LB.
8. MTN. Press Release: Microbicide Trials Network Statement on Decision to Discontinue Use of Oral Tenofovir Tablets in Voice, a Major HIV Prevention Study in Women. Microbicide Trials Network (MTN), Pittsburgh, 2011.
9. Kashuba AD, Patterson KB, Dumond JB, et al. Pre-exposure prophylaxis for HIV prevention: how to predict success. Lancet. Published Online First: 6 December 2011. doi:10.1016/S0140-6736 (11)61852-7
10. Underhill K, Operario D, Mimiaga MJ, et al. Implementation Science of pre-exposure prophylaxis: preparing for public use. Curr HIV/AIDS Rep 2010;7:210-19.
11. Kim SC, Becker S, Dieffenbach C, et al. Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities. J Int AIDS Soc 2010;13:24.
12. Buchbinder S, Liu A. Pre-exposure prophylaxis and the promise of combination prevention approaches. AIDS Behav 2011;15(Suppl 1): S72-9.
13. Coates TJ, Richter L, Caceres C. Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet 2008;372:669-84.
14. Myers GM, Mayer KH. Oral preexposure Anti-HIV prophylaxis for high-risk U.S. Populations: current considerations in light of new findings. AIDS Patient Care STDS 2011;25:63-71.
15. Bertozzi SM, Laga M, Bautista-Arredondo S, et al. Making HIV prevention programmes work. Lancet 2008;372:831-44.
16. Eisingerich AB, Wheelock A, Gomez GB, et al. Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a Multinational study. PLoS ONE 2012;7: e28238.
17. Greenhalgh T, Taylor R. How to read a paper: papers that go beyond numbers (qualitative research). BMJ 1997;315:740-3. (Pubitemid 27405832)
18. Pope C, Ziebland S, Mays N. Qualitative research in health care. BMJ 2000;320:114-16.
19. Silverman D. Interpreting Qualitative Data: Methods for Analyzing Talk, Text, and Interaction. 3rd edn. London: Sage, 2001.
20. Flick U. An Introduction to Qualitative Research. 4th edn. London: Sage, 2009.
21. Hoffman S, Cooper D, Ramjee G, et al. Microbicide acceptability: insights for future directions from providers and policy makers. AIDS Educ Prev 2008;20:188-202. (Pubitemid 351679863)
22. Orner P, Harries J, Cooper D, et al. Challenges to microbicide introduction in South Africa. Soc Sci Med 2006;63:968-78.
23. Piot P, Bartos M, Larson H, et al. Coming to terms with complexity: a call to action for HIV prevention. Lancet 2008;372:845-59.
24. Merson MH, O'Malley J, Serwadda D, et al. The history and challenge of HIV prevention. Lancet 2008;372:475-88.
25. Padian NS, McCoy SI, Manian S, et al. Evaluation of large-scale combination HIV prevention programs: essential issues. J Acquir Immune Defic Syndr 2011;58:e23-8.
26. Rankin WW, Brennan S, Schell E, et al. The stigma of being HIV-positive in Africa. PLoS Med 2005;2:e247.
27. Ekstrand M, Bharat S, Ramakrishna J, et al. Blame, symbolic stigma and HIV Misconceptions are associated with support for Coercive measures in urban India. AIDS Behav 2012;16:1-11.
28. Schwartländer B, Stover J, Hallett T, et al Investment Framework Study Group. Towards an improved investment approach for an effective response to HIV/AIDS. Lancet 2011;377:2031-41.